Search

Displaying results 6811 - 6820 of 8410 in total
  1. Drug

    Camellia japonica seed oil

    go.drugbank.com/drugs/DB14308
    Investigational

    It is not an approved drug.

  2. Drug

    Chamaecyparis obtusa wood oil

    go.drugbank.com/drugs/DB14341
    Investigational

    It is not an approved drug.

    Products: Phytoncide Su
  3. Drug

    Rosa centifolia flower oil

    go.drugbank.com/drugs/DB14363
    Investigational

    It is not an approved drug.

  4. Drug

    Olaflur

    go.drugbank.com/drugs/DB13290
    Investigational

    Olaflur which is also referred to as elmex gel is an ingredient used in toothpaste which helps in the prevention of dental caries.

  5. Drug

    AL-034

    go.drugbank.com/drugs/DB17471
    Investigational

    AL-034 (TQ-A3334) is an oral toll-like receptor 7 agonist developed for the treatment of chronic hepatitis B (CHB) viral infection.

  6. Drug

    NY-ESO-1 peptide vaccine

    go.drugbank.com/drugs/DB17498
    Investigational

    NY-ESO-1 peptide vaccine is an investigational cancer immunotherapy. It contains a peptide derived from the cancer-testis antigen (NY-ESO-1).

  7. Drug

    Roledumab

    go.drugbank.com/drugs/DB16317
    Investigational

    Roledumab is under investigation in clinical trial NCT02287896 (Pharmacokinetics and Safety of Roledumab in Rhd-negative Pregnant Women Carrying an Rhd-positive Foetus).

    Synonyms: Immunoglobulin g1-kappa, anti-(homo sapiens rhd(rhesus blood group d antigen, rhd, cd240d)), homo sapiens monoclonal antibody
  8. Drug

    Virginiamycin

    go.drugbank.com/drugs/DB11476
    ExperimentalVet approved

    According to a USDA study, antibiotics can save as much as 30% in feed costs among young swine.

  9. Drug

    Osanetant

    go.drugbank.com/drugs/DB04872
    Investigational

    In a review of its R&D portfolio, the company announced in August 2005 that it would cease any further development of osanetant. … This follows an earlier decision to discontinue development of eplivanserin for schizophrenia.

  10. Drug

    EMZ702

    go.drugbank.com/drugs/DB05021
    Investigational

    EMZ702, a non-toxic agent that has strong anti-viral synergy with interferon, is an ideal candidate for combination with current standard hepatitis C treatments. … EMZ702 has an excellent safety profile and the combination of EMZ702 with interferon and ribavirin in surrogate models for hepatitis C has demonstrated a two to three fold increase in anti-viral potency